問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of General Internal Medicine

Division of Infectious Disease

China Medical University Hospital (在職)

Division of Infectious Disease

更新時間：2023-09-19

蔡宏津
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡宏津

List

34Cases

2024-05-03 - 2030-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2025-01-01 - 2031-01-26

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2033-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2026-07-01 - 2033-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2024-11-15 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-01-17 - 2030-01-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-03-01 - 2028-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2012-07-01 - 2014-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-01-30 - 2022-03-31

Phase II

A phase II,Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of UB-612 Vaccine against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers

  • Condition/Disease

    COVID-19

  • Test Drug

    UB-612

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2020-06-01 - 2022-12-31

Phase I

A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

  • Condition/Disease

    Anti-infectives for systemic use

  • Test Drug

    UB-421 SC (dB4C7C22-6 mAb)

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB